{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:38:14Z","timestamp":1773920294814,"version":"3.50.1"},"reference-count":164,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The therapeutic landscape of non\u2013small cell lung cancer (NSCLC) has been profoundly transformed by the widespread adoption of molecular profiling and the development of targeted therapies, like tyrosine kinase inhibitors (TKIs), antibody\u2013drug conjugates (ADCs), and bispecific antibodies (BsAbs). These agents have significantly improved survival and quality of life in molecularly selected subgroups, potentially converting NSCLC into a chronic disease requiring prolonged treatment exposure. However, extended survival has led to increasing recognition of cancer treatment\u2013related cardiovascular (CV) disease as a clinically relevant and sometimes dose-limiting complication. Unlike conventional chemotherapy, CV toxicities associated with targeted therapies frequently arise from on-target or off-target interference with signaling pathways that are essential for myocardial survival, endothelial function, vascular regulation, and the cardiac conduction system. From common pathophysiological mechanisms, a broad spectrum of clinical manifestations arises, ranging from asymptomatic electrocardiographic changes to arterial hypertension, dyslipidemia, venous thromboembolism, arrhythmias, and heart failure. This review provides a comprehensive overview of CV toxicities associated with targeted therapies in NSCLC, integrating mechanistic insights with clinical evidence. We summarize class-specific CV risk profiles across EGFR, ALK\/ROS1, RET, MET, NTRK, BRAF, and KRAS-G12C inhibitors, as well as ADCs and BsAbs, highlighting both shared and distinct patterns of cardiotoxicity. As targeted therapies continue to expand across disease stages and treatment lines, CV toxicity is expected to play an increasingly important role in therapeutic decision-making. Integrating CV considerations into oncologic care is therefore essential to preserve treatment continuity, optimize long-term outcomes, and maximize the benefits of modern targeted therapies in NSCLC.<\/jats:p>","DOI":"10.3389\/fphar.2026.1790897","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:50:51Z","timestamp":1773903051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapies in non\u2013small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management"],"prefix":"10.3389","volume":"17","author":[{"given":"Simone","family":"Nardin","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]},{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova","place":["Genova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Vezzoli","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]},{"name":"Department of Translational Medicine, University of Piemonte Orientale","place":["Novara, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Cognolato","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]},{"name":"Department of Translational Medicine, University of Piemonte Orientale","place":["Novara, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocco","family":"Mollace","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Humanitas Gavazzeni","place":["Bergamo, Italy"]},{"name":"Department of Experimental Medicine, University of Rome Tor Vergata","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Ramella Pollone","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova","place":["Genova, Italy"]},{"name":"U.O. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Biello","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Cao","sequence":"additional","affiliation":[{"name":"Cardiology Unit, Humanitas Gavazzeni","place":["Bergamo, Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tagliamento","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova","place":["Genova, Italy"]},{"name":"U.O. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Sarocchi","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Unit, IRCCS San Martino Policlinic Hospital","place":["Genova, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Pagnesi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Institute of Cardiology, ASST Spedali Civili, University of Brescia","place":["Brescia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Verdoia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nuovo Ospedale degli Infermi, ASL Biella","place":["Biella, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Conte","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]},{"name":"Department of Translational Medicine, University of Piemonte Orientale","place":["Novara, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia","place":["Brescia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Genova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova","place":["Genova, Italy"]},{"name":"U.O. Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Gennari","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Maggiore University Hospital","place":["Novara, Italy"]},{"name":"Department of Translational Medicine, University of Piemonte Orientale","place":["Novara, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Nardin","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele","place":["Milan, Italy"]},{"name":"Internal Medicine, Department of Medicine, ASST Spedali Civili di Brescia","place":["Brescia, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jtho.2020.04.033","article-title":"Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC","volume":"15","author":"Al-Samkari","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcm.2019.01.001","article-title":"Effect of statins on atherosclerotic plaque","volume":"29","author":"Almeida","year":"2019","journal-title":"Trends cardiovasc. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/j.1538-7836.2004.00871.x","article-title":"A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer","volume":"2","author":"Altinbas","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40261-024-01379-7","article-title":"Expert consensus on the management of adverse events of lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer","volume":"44","author":"Arriola","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"B8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/curroncol32040198","article-title":"Pathogenesis, diagnosis, and management of cytokine release syndrome in patients with cancer: focus on infectious disease considerations","volume":"32","author":"Arvanitis","year":"2025","journal-title":"Curr. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur. J. Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American heart association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"H702","DOI":"10.1152\/ajpheart.00231.2022","article-title":"Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress","volume":"323","author":"Bikomeye","year":"2022","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca. Cancer J. Clin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.thromres.2017.03.012","article-title":"Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study","volume":"153","author":"Brunson","year":"2017","journal-title":"Thromb. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/cdt-20-165","article-title":"The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology","volume":"10","author":"Burrage","year":"2020","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/14796694.2024.2370239","article-title":"Cardiovascular toxicity of Anaplastic lymphoma kinase inhibitors for patients with non-small cell lung cancer: a network meta-analysis","volume":"21","author":"Cai","year":"2025","journal-title":"Futur. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11906-018-0871-1","article-title":"Management of VEGF-targeted therapy-induced hypertension","volume":"20","author":"Caletti","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","article-title":"Cardioprotective effect of statins in patients with HER2-Positive breast cancer receiving trastuzumab therapy","volume":"35","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"Can. J. Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","article-title":"VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications","volume":"24","author":"Camarda","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e05","DOI":"10.15420\/ecr.2024.49","article-title":"Cardio-oncology: emerging concepts in cardiovascular sequelae of cancer therapies, translational research and reverse cardio-oncology","volume":"20","author":"Camilli","year":"2025","journal-title":"Eur. Cardiol. Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11936-016-0465-7","article-title":"Exercise and aerobic fitness to reduce cancer-related cardiovascular toxicity","volume":"18","author":"Campia","year":"2016","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e472792","DOI":"10.1200\/EDBK-25-472792","article-title":"Bispecific antibodies in non\u2013small cell lung cancer: from targeted innovation to real-world integration","volume":"45","author":"Carlisle","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. B"},{"key":"B23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.thromres.2020.09.021","article-title":"High plasma levels of soluble P-Selectin and factor VIII predict venous thromboembolism in non-small cell lung cancer patients: the thrombo-nsclc risk score","volume":"196","author":"Castell\u00f3n Rubio","year":"2020","journal-title":"Thromb. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","article-title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial","volume":"406","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","article-title":"ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS)","volume":"21","author":"Chiari","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR -Mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3390\/ph18091399","article-title":"Cardiotoxicity induced by anticancer therapies: a call for integrated cardio-oncology practice","volume":"18","author":"Ciappina","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/14737140.2024.2357814","article-title":"The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis","volume":"24","author":"Ciccarese","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"23","author":"Cozma","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"Ca. Cancer J. Clin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","article-title":"Endothelial function and dysfunction","volume":"115","author":"Deanfield","year":"2007","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2020.03.019","article-title":"Myocardial interstitial fibrosis in nonischemic heart disease, part 3\/4","volume":"75","author":"D\u00edez","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1136\/bmj.38142.554479.AE","article-title":"Mortality in relation to smoking: 50 years\u2019 observations on Male British doctors","volume":"328","author":"Doll","year":"2004","journal-title":"BMJ"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.4.9","article-title":"Larotrectinib and entrectinib: TRK inhibitors for the treatment of pediatric and adult patients with NTRK gene fusion","volume":"11","author":"Dunn","year":"2020","journal-title":"J. Adv. Pract. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/joa3.12741","article-title":"Pharmacological activation of the hERG K+ channel for the management of the long QT syndrome: a review","volume":"38","author":"El Harchi","year":"2022","journal-title":"J. Arrhythmia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"11795549251331759","DOI":"10.1177\/11795549251331759","article-title":"Potency and safety of KRAS G12C inhibitors in solid tumors: a systematic review","volume":"19","author":"El Zaitouni","year":"2025","journal-title":"Clin. Med. Insights Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","article-title":"Ivonescimab plus chemotherapy in non\u2013small cell lung cancer with EGFR variant","volume":"332","author":"Fang","year":"2024","journal-title":"JAMA"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"188","DOI":"10.37349\/emed.2022.00085","article-title":"Reactive oxygen species in cardiovascular diseases: an update","volume":"3","author":"Fei","year":"2022","journal-title":"Explor. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card. Electrophysiol. Clin."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mam.2018.07.001","article-title":"Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities","volume":"65","author":"Frangogiannis","year":"2019","journal-title":"Mol. Asp. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/ijms25052973","article-title":"New insights into endothelial dysfunction in cardiometabolic diseases: potential mechanisms and clinical implications","volume":"25","author":"Gallo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-Cell therapy for cancer and heart","volume":"74","author":"Ganatra","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-Cell antineoplastic therapies","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"997660","DOI":"10.3389\/fcvm.2022.997660","article-title":"Cardiotoxicity induced by immune checkpoint inhibitor: the complete insight into mechanisms, monitoring, diagnosis, and treatment","volume":"9","author":"Ganesh","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(18)32225-6","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease stu","volume":"392","year":"2018","journal-title":"Lancet London, Engl."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051418","article-title":"Circulating MicroRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin","volume":"9","author":"Gioffr\u00e9","year":"2020","journal-title":"J. Clin. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb. Haemost."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jacc.2018.02.021","article-title":"Myocardial interstitial fibrosis in heart failure","volume":"71","author":"Gonz\u00e1lez","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10928-025-10010-x","article-title":"QT interval prolongation: clinical assessment, risk factors and quantitative pharmacological considerations","volume":"52","author":"Gotta","year":"2025","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B59","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/ehf2.12450","article-title":"Health care utilization and mortality associated with heart failure-related admissions among cancer patients","volume":"6","author":"Guha","year":"2019","journal-title":"Esc. Hear. Fail."},{"key":"B60","doi-asserted-by":"publisher","first-page":"ehae666.2693","DOI":"10.1093\/eurheartj\/ehae666.2693","article-title":"External validation of the HFA-ICOS risk stratification tool for prediction of cardiovascular complications after cancer treatment","volume":"45","author":"Gynnild","year":"2024","journal-title":"Eur. Heart J."},{"key":"B61","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e2400338","DOI":"10.1200\/GO-24-00338","article-title":"Real-world survival outcomes in non\u2013small cell lung cancer: the impact of genomic testing and targeted therapies in a Latin American middle-income country","volume":"10","author":"Hernandez-Martinez","year":"2024","journal-title":"JCO Glob. Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an international cardio-oncology society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fphar.2020.00740","article-title":"Troponins and natriuretic peptides in cardio-oncology patients\u2014data from the ECoR registry","volume":"11","author":"Hinrichs","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14740338.2024.2392003","article-title":"Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database","volume":"24","author":"Hou","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"B67","doi-asserted-by":"publisher","first-page":"694711","DOI":"10.3389\/fcvm.2021.694711","article-title":"Updates on anticancer therapy-mediated vascular toxicity and new Horizons in therapeutic strategies","volume":"8","author":"Hsu","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B68","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","article-title":"Advances in molecular pathology and therapy of non-small cell lung cancer","volume":"10","author":"Huang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jacbts.2019.02.006","article-title":"Fibroblasts in the infarcted, remodeling, and failing heart","volume":"4","author":"Humeres","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/01.HYP.35.1.173","article-title":"Ion channels and vascular tone","volume":"35","author":"Jackson","year":"2000","journal-title":"Hypertension"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e2543107","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2 -Mutant metastatic non\u2013small cell lung cancer with or without brain metastases","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br. J. Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40959-025-00363-0","article-title":"Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the Hellenic cardiac society","volume":"11","author":"Keramida","year":"2025","journal-title":"Cardio-Oncology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","article-title":"How to diagnose and manage QT prolongation in cancer patients","volume":"3","author":"Kim","year":"2021","journal-title":"JACC. CardioOncology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The present and future of bispecific antibodies for cancer therapy","volume":"23","author":"Klein","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.cllc.2023.09.007","article-title":"Smoking, diabetes mellitus, and previous cardiovascular disease as predictors of anticancer treatment-induced cardiotoxicity in Non\u2013small-cell lung cancer: a real-world study","volume":"25","author":"Kobat","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s44161-025-00698-y","article-title":"Heart failure-specific cardiac fibroblasts contribute to cardiac dysfunction via the MYC\u2013CXCL1\u2013CXCR2 axis","volume":"4","author":"Komuro","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC. CardioOncology"},{"key":"B81","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","article-title":"Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction","volume":"153","author":"Kunimasa","year":"2021","journal-title":"Lung Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B83","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1196\/annals.1338.023","article-title":"Oxidative damage in mitochondrial DNA is not extensive","volume":"1042","author":"Lim","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e043620","DOI":"10.1161\/JAHA.125.043620","article-title":"Increased cardiovascular risk with lorlatinib in patients with ALK\u2010Mutated lung cancer: a real\u2010world comparative study","volume":"14","author":"Lin","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"B85","doi-asserted-by":"publisher","first-page":"S437","DOI":"10.4103\/0973-1482.176174","article-title":"Low molecular weight heparin in treating patients with lung cancer received chemotherapy","volume":"14","author":"Liu","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jacc.2006.06.034","article-title":"QT interval duration remains a major risk factor in long QT syndrome patients\u2217\u2217Editorials published in the journal of the American college of cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American coll","volume":"48","author":"Locati","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1378010","DOI":"10.3389\/fphar.2024.1378010","article-title":"Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database","volume":"15","author":"Long","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"189008","DOI":"10.1016\/j.bbcan.2023.189008","article-title":"Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy","volume":"1878","author":"Luo","year":"2023","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the european society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"B90","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 focused update of the 2025 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"","journal-title":"Atherosclerosis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"","journal-title":"Eur. Heart J."},{"key":"B93","first-page":"67","article-title":"Management of KRAS-Mutated non-small cell lung cancer","volume":"22","author":"Malhotra","year":"2024","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"B96","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/life13020366","article-title":"Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors","volume":"13","author":"Mihalcea","year":"2023","journal-title":"Life Basel, Switz."},{"key":"B97","doi-asserted-by":"publisher","first-page":"101830","DOI":"10.1016\/j.esmoop.2023.101830","article-title":"Risk profiles and incidence of cardiovascular events across different cancer types","volume":"8","author":"Mitchell","year":"2023","journal-title":"ESMO Open"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41421-024-00738-0","article-title":"Ion channel traffic jams: the significance of trafficking deficiency in long QT syndrome","volume":"11","author":"Mond\u00e9jar-Parre\u00f1o","year":"2025","journal-title":"Cell Discov."},{"key":"B99","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.abb.2014.06.011","article-title":"Endothelium-derived nitric oxide (NO) activates the NO-epidermal growth factor receptor-mediated signaling pathway in bradykinin-stimulated angiogenesis","volume":"558","author":"Moraes","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"B100","doi-asserted-by":"publisher","first-page":"223","DOI":"10.31083\/j.fbl2906223","article-title":"Endothelial cell dysfunction: onset, progression, and consequences","volume":"29","author":"Naderi-Meshkin","year":"2024","journal-title":"Front. Biosci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"102969","DOI":"10.1016\/j.critrevonc.2020.102969","article-title":"A user\u2019s guide to lorlatinib","volume":"151","author":"Nagasaka","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/jcdd12070270","article-title":"Navigating cardiotoxicity in immune checkpoint inhibitors: from diagnosis to long-term management","volume":"12","author":"Nardin","year":"2025","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","article-title":"Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-Altered cancers","volume":"4","author":"Nardo","year":"2023","journal-title":"Cell Rep. Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1177\/10781552221147500","article-title":"An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)","volume":"29","author":"Nguyen","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B106","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B107","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11523-022-00912-y","article-title":"Management of peripheral edema in patients with MET exon 14-Mutated non-small cell lung cancer treated with small molecule MET inhibitors","volume":"17","author":"Nishio","year":"2022","journal-title":"Target. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor\u2013associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"B111","doi-asserted-by":"publisher","first-page":"104835","DOI":"10.1016\/j.critrevonc.2025.104835","article-title":"Cardiac and vascular toxicity of amivantamab in non-small cell lung cancer (NSCLC): a systematic review","volume":"213","author":"Papassotiriou","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-Mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"309","DOI":"10.12688\/f1000research.162353.1","article-title":"Optimizing cardiovascular treatment in non-small cell lung cancer: a comprehensive computational approach for assessment of drug-drug interactions between tyrosine kinase inhibitors and cardiovascular drugs","volume":"14","author":"Patil","year":"2025","journal-title":"Research"},{"key":"B114","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/1759-7714.14824","article-title":"Efficacy and safety of Anaplastic lymphoma kinase inhibitors for non\u2013small cell lung cancer: a systematic review and network meta\u2010analysis","volume":"14","author":"Peng","year":"2023","journal-title":"Thorac. Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","article-title":"Mitochondrial dysfunction and oxidative stress in heart disease","volume":"51","author":"Peoples","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"11517","DOI":"10.3390\/ijms262311517","article-title":"Advances in targeted therapy for non-small-cell lung cancer: current progress and future directions","volume":"26","author":"Peshin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta\u2010S\u00e1nchez","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the european society of cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"B119","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jacc.2004.11.075","article-title":"Women and ischemic heart disease","volume":"47","author":"Quyyumi","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B121","doi-asserted-by":"publisher","first-page":"101194","DOI":"10.1016\/j.mam.2023.101194","article-title":"Cardiac fibrosis in heart failure: focus on non-invasive diagnosis and emerging therapeutic strategies","volume":"93","author":"Ravassa","year":"2023","journal-title":"Mol. Asp. Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"B124","doi-asserted-by":"publisher","first-page":"100891","DOI":"10.1016\/j.ctarc.2025.100891","article-title":"Targeted therapy for non-small cell lung cancer (NSCLC) in a real-world setting: a single practice experience","volume":"43","author":"Rothe","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"B125","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12032-018-1120-9","article-title":"Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients","volume":"35","author":"Rupa-Matysek","year":"2018","journal-title":"Med. Oncol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"JACC. CardioOncology"},{"key":"B127","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11864-021-00869-6","article-title":"Cardiovascular complications associated with contemporary lung cancer treatments","volume":"22","author":"Sase","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11886-023-01845-2","article-title":"Cardiovascular toxicities associated with tyrosine kinase inhibitors","volume":"25","author":"Sayegh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"B129","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.cir.88.2.782","article-title":"Diagnostic criteria for the long QT syndrome. An update","volume":"88","author":"Schwartz","year":"1993","journal-title":"Circulation"},{"key":"B130","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1161\/CIRCEP.111.962019","article-title":"Long-QT syndrome","volume":"5","author":"Schwartz","year":"2012","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"103257","DOI":"10.1016\/j.cpcardiol.2025.103257","article-title":"Balancing hope and heart: an umbrella review of cardiotoxicity in immune checkpoint inhibitor cancer therapies","volume":"51","author":"Sethi","year":"2026","journal-title":"Curr. Probl. Cardiol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK -Positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.1093\/eurheartj\/ehu427","article-title":"2014 williams harvey lecture: importance of coronary vasomotion abnormalities--from bench to bedside","volume":"35","author":"Shimokawa","year":"2014","journal-title":"Eur. Heart J."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B136","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.3390\/ijms21197195","article-title":"Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review","volume":"21","author":"S\u0142awi\u0144ski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1200\/JCO.2015.64.9970","article-title":"Bispecific T-Cell engagers (BiTEs) as treatment of B-Cell lymphoma","volume":"34","author":"Smits","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1161\/CIRCOUTCOMES.110.957571","article-title":"Population impact of heart failure and the Most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004)","volume":"3","author":"Stewart","year":"2010","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"B140","doi-asserted-by":"publisher","first-page":"oyaf331","DOI":"10.1093\/oncolo\/oyaf331","article-title":"Antibody drugs conjugates in non\u2013small cell lung cancer: current status and challenges","volume":"30","author":"Syal","year":"2025","journal-title":"Oncologist"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1491990","DOI":"10.3389\/fphar.2025.1491990","article-title":"Comparative safety profile of tyrosine kinase inhibitors in NSCLC: a network meta-analysis of hypertension and thrombotic risks","volume":"16","author":"Tan","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.3390\/cancers17213443","article-title":"A new era, new risks: the cardio-oncology perspective on immunotherapy in non-small cell lung cancer","volume":"17","author":"Tarantini","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-Altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"key":"B146","doi-asserted-by":"publisher","first-page":"1577607","DOI":"10.3389\/fonc.2025.1577607","article-title":"Real-world analysis of the efficacy and safety of lorlatinib in ALK-Positive non-small cell lung cancer patients in China","volume":"15","author":"Tian","year":"2025","journal-title":"Front. Oncol."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta\u2010analysis of more than 20 000 patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"B148","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"B149","doi-asserted-by":"publisher","first-page":"1431023","DOI":"10.3389\/fonc.2024.1431023","article-title":"Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer","volume":"14","author":"Wang","year":"","journal-title":"Front. Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1426796","DOI":"10.3389\/fonc.2024.1426796","article-title":"EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring","volume":"14","author":"Wang","year":"","journal-title":"Front. Oncol."},{"key":"B151","unstructured":"QTdrugs list\n          \n          \n            \n              Woosley\n              R.\n            \n            \n              Heise\n              C.\n            \n            \n              Gallo\n              T.\n            \n            \n              Woosley\n              R.\n            \n            \n              Lambson\n              J.\n            \n            \n              Romero\n              K."},{"key":"B152","doi-asserted-by":"publisher","first-page":"e001493","DOI":"10.1136\/bmjresp-2022-001493","article-title":"Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review","volume":"10","author":"Xiong","year":"2023","journal-title":"BMJ Open Respir. Res."},{"key":"B153","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B154","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall survival with Amivantamab\u2013Lazertinib in EGFR -Mutated advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B157","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4103\/0973-1482.191627","article-title":"Adjuvant therapy with heparin in patients with lung cancer without indication for anticoagulants: a systematic review of the literature with meta-analysis","volume":"12","author":"Yu","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"B158","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur. Heart J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1343582","DOI":"10.3389\/fphar.2024.1343582","article-title":"Effect of ezetimibe\u2013statin combination therapy vs. statin monotherapy on coronary atheroma phenotype and lumen stenosis in patients with coronary artery disease: a meta-analysis and trial sequential analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1056\/NEJMc2314937","article-title":"NVTE with Amivantamab plus Cheaotherapy in NSCLc","volume":"390","author":"Zhou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B162","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"B163","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/CIRCRESAHA.110.223917","article-title":"Neuregulin\/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells","volume":"107","author":"Zhu","year":"2010","journal-title":"Circ. Res."},{"key":"B164","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","article-title":"Mitochondrial dysfunction: mechanisms and advances in therapy","volume":"9","author":"Zong","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:50:53Z","timestamp":1773903053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1790897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":164,"alternative-id":["10.3389\/fphar.2026.1790897"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1790897","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1790897"}}